MedTrace Logo

Thyroid Dysfunction and Nivolumab Reponse in NSCLC

NCT04470440 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 134

Last updated 2020-07-14

No results posted yet for this study

Summary

This is an observational, retrospective and monocentric study, conducted at the university Hospital of Brest The primary objective is to assess the association between the occurrence of thyroid dysfunction in patients treated with Nivolumab® for a non-small cell lung cancer and prognosis and therapeutic response The second objective is to assess prognosis and therapeutic response according to severity and subtype of thyroid dysfunction

Conditions

  • Non Small Cell Lung Cancer Metastatic
  • Treatment Adverse Effect
  • Thyroid Dysfunction
  • Immune Checkpoint Inhibitor
  • Prognosis

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2019-11-05
Completion
2019-11-05

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04470440 on ClinicalTrials.gov